Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA

Gene Therapy

Volumn 13, Issue 22, 2006, Pages 1579-1586

  Carlisle, R C ^a   Briggs, S S ^a   Hale, A B ^a   Green, N K ^b   Fisher, K D ^a   Etrych, T ^c   Ulbrich, K ^c   Mautner, V ^d   Seymour, L W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Hybrid Systems Ltd   (United Kingdom)

^c INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; GLYCOPROTEIN E1; GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY; POLYMER; POLYPLEX; UNCLASSIFIED DRUG; VIRUS DNA;

5' UNTRANSLATED REGION; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CONTROLLED STUDY; COVALENT BOND; EXPERIMENTAL NEOPLASM; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS INFECTION; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY REACTIONS; DNA, VIRAL; GENE THERAPY; GENETIC ENGINEERING; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS; TRANSDUCTION, GENETIC; TRANSFECTION; VACCINES, SYNTHETIC;

ADENOVIRIDAE;

EID: 33750629623     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302814     Document Type: Article

References (32)

1. Niculescu-Duvaz I, Cooper RG, Stribbling SM, Heyes JA, Metcalfe JA, Springer CJ. Recent developments in gene-directed enzyme prodrug therapy (GDEPARTMENT) for cancer. Curr Opin Mol Ther 1999; 1: 480-486.
2. Kirn D. Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer. Oncogene 2000; 19: 6660-6669.
3. Nettelbeck DM. Virotherapeutics: Conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003; 14: 577-584.
4. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933-946.
5. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): Results of phase I and II trials. Expert Opin Biol Ther 2001; 1: 525-538.
6. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005; 24: 7802-7816.
7. Barzon L, Zanusso M, Colombo F, Palu G. Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther 2006; 13: 539-554.
8. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003; 41: 5046-5052.
9. Christ M, Lusky M, Stoeckel F, Dreyer D, Dieterle A, Michou AI et al. Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response. Immunol Lett 1997; 57: 19-25.
10. Stallwood Y, Fisher KD, Gallimore PH, Mautner V. Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients. Gene Therapy 2000; 7: 637-643.
11. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Therapy 2001; 8: 341-348.
12. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Therapy 2004; 11: 1256-1263.
13. Kreppel F, Gackowski J, Schmidt E, Kochanek S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther 2005; 12: 107-117.
14. Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O'Riordan CR. Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice. Hum Gene Ther 1999; 10: 2615-2626.
15. Oupicky D, Ogris M, Howard KA, Dash PR, Ulbrich K, Seymour LW. Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther 2002; 5: 463-472.
16. Fisher KD, Ulbrich K, Subr V, Ward CM, Mautner V, Blakey D et al. A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression. Gene Therapy 2000; 7: 1337-1343.
17. Carlisle RC, Etrych T, Briggs SS, Preece JA, Ulbrich K, Seymour LW. Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction. J Gene Med 2004; 6: 337-344.
18. Desiderio SV, Kelly Jr TJ. Structure of the linkage between adenovirus DNA and the 55 000 molecular weight terminal protein. J Mol Biol 1981; 145: 319-337.
19. Pronk R, van der Vliet PC. The adenovirus terminal protein influences binding of replication proteins and changes the origin structure. Nucleic Acids Res 1993; 21: 2293-2300.
20. Pronk R, Stuiver MH, van der Vliet PC. Adenovirus DNA replication: The function of the covalently bound terminal protein. Chromosoma 1992; 102: S39-S45.
21. Angeletti PC, Engler JA. Adenovirus preterminal protein binds to the CAD enzyme at active sites of viral DNA replication on the nuclear matrix. J Virol 1998; 72: 2896-2904.
22. Schaack J, Ho WY, Freimuth P, Shenk T. Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA. Genes Dev 1990; 4: 1197-1208.
23. Schaack J, Shenk T. Adenovirus terminal protein mediates efficient and timely activation of viral transcription. Curr Top Microbiol Immunol 1989; 144: 185-190.
24. Webster A, Leith IR, Nicholson J, Hounsell J, Hay RT. Role of preterminal protein processing in adenovirus replication. J Virol 1997; 71: 6381-6389.
25. Sharp PA, Moore C, Haverty JL. The infectivity of adenovirus 5 DNA-protein complex. Virology 1976; 75: 442-456.
26. Lieber A, Kay MA, Li ZY. Nuclear import of moloney murine leukemia virus DNA mediated by adenovirus preterminal protein is not sufficient for efficient retroviral transduction in nondividing cells. J Virol 2000; 74: 721-734.
27. Fredman JN, Engler JA. Adenovirus precursor to terminal protein interacts with the nuclear matrix in vivo and in vitro. J Virol 1993; 67: 3384-3395.
28. Briggs SS, Carlisle RC, Ulbrich K, Preece JA, Seymour LW. Bioreversible polymer coating for improved circulation kinetics of transfection active non-viral vectors. European Society for Gene Therapy, Prague, November 2005; Poster 156: 83.
29. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55 kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000; 60: 6359-6366.
30. Oupicky D, Ogris M, Seymour LW. Development of long-circulating polyelectrolyte complexes for systemic delivery of genes. J Drug Target 2002; 10: 93-98.
31. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-6392.
32. Crosdale D, Fisher K, Seymour L, Norman K, Newman C, Hellewell P. Selectin-mediated targeting of DNA complexes to inflamed endothelium in vivo. Proceedings of the European Society of Gene Therapy, 11th Annual Congress, Edinburgh 2003; poster 33: 48.